

Name of compounded product					
Consider active pharmaceutical ingredie			Sheets (SD		
API	DIN	SDS		Manufacturer	
		☐ Yes	☐ No		
			П.,		
		Yes	☐ No		
		Yes	□No		
		☐ Yes	☐ No		
NIOSH Classification?		Is this toxic	to reproduc	tion?	
Yes No			No		
Table 1 Table 2 Table 3					
WHIMIS Health Hazard?					
Yes No					
Description (as per Section 2 of SDS)					
Deviles to the second s		اد			
Product monograph contraindications, w	arnings, or precaut	tions?			

Updated October 2022 1

Simple	S this compound only prepared occasionally?  Yes No			
Describe how often this compound is prepared (for example, daily, weekly, monthly).	Are there only small quantities of ingredients being prepared?  Yes No			
On average, what quantity of this preparation is being prepared at a time?	Do the concentration of ingredients in the product present a health risk to the compounder?  Yes No			
Physical characteristics of the ingredients  Liquid Volatile Liquid  Semi-Solid Solid Powder  Cream/Ointment				
Does preparation require special education or competencie  Yes No	s for your compounding personnel?			
If yes, then describe this in the master formulation record an	nd consider whether level B or C requirements apply:			
Are there verification steps during compounding?	Do you have appropriate facilities and equipment to			
Yes No	prepare this compound?			
	Yes No			
Is ventilation required for preparation (as per section 8 of SDS or product monograph)?  SDS Yes No  Product monograph Yes No				
Is your workflow uninterrupted?				
☐ Yes ☐ No				
If no, describe your processes to address the situation in order to meet standards:				

Updated October 2022 2

Yes No	Yes No
Mask Yes No Type  Eye protection Yes No	
Other PPE necessary (head, hair, or shoe covers)	
Is an eye wash station required?  Yes No	Is a safety shower required?  Yes No
Risk level assigned  Level A Level B Level C	
Rationale and other risk mitigation measures	
Compounding supervisor signature	Date
	Day / Month / Year

Updated October 2022 3